Is Neuland Laboratories (NEULANDLAB) overvalued or fairly valued?

MarketChacha shows Neuland Laboratories's valuation in context — a forward P/E of about 40.6, a price-to-book of about 12.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Neuland Laboratories's revenue?

Neuland Laboratories reported revenue of ₹1,477 Cr for FY2025, with net profit of ₹260 Cr, per official filings.

What is the share price of Neuland Laboratories (NEULANDLAB)?

Neuland Laboratories last traded at ₹18,466.00 (-2.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Neuland Laboratories

NEULANDLAB · NSE · Pharma · India

₹18,466.00-2.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerNEULANDLAB

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees2,183

HeadquartersHyderabad, India

Market cap₹23,692 Cr

P/B12.6

Volume17.41K

Websitewww.neulandlabs.com

Filings tracked0

About Neuland Laboratories

Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters37.8%
Institutions28.5%
Public & other33.8%

67 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend6.7% → 17.6%

Margin has expanded by about 10.9 points — the business is getting more profitable.

Growth qualityrev 16% · PAT 60%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹597 Cr · EPS 89.79

Est. earnings growth +18.9%

Next fiscal year

Rev ₹2,780 Cr · EPS 454.89

Est. earnings growth +39.2%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹11,500.0052-wk range₹20,089.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹23,692 Cr

Day change

-2.5%

Fwd P/E

40.6

P/B

12.6

Div yield

0.18%

Beta

-0.32

Revenue (FY2025)

₹1,477 Cr

Net margin

17.6%

Revenue CAGR (3y)

+15.8%

Profit CAGR (3y)

+59.7%

Net profit (FY2025)

₹260 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about NEULANDLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2025	₹1,477 Cr	₹260 Cr	17.6%
FY2024	₹1,559 Cr	₹300 Cr	19.3%
FY2023	₹1,191 Cr	₹164 Cr	13.7%
FY2022	₹951 Cr	₹64 Cr	6.7%

Quarterly

Period	Revenue	Net profit	Net margin
2025Q4	₹440 Cr	₹41 Cr	9.2%
2025Q3	₹514 Cr	₹97 Cr	18.8%
2025Q2	₹293 Cr	₹14 Cr	4.7%
2025Q1	₹328 Cr	₹28 Cr	8.5%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.